Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Alveus Therapeutics ApS
APS
Active
CVR 44689790
Palægade 4, 1261
København K
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2024 · 2 years old
10 employees
Monitor
Share
Denmark
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Alveus Therapeutics ApS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Current (3)
RK
Rajkumar Kannan
Chief Executive Officer
Chief Executive Officer
2025
NR
New Rhein Healthcare 2021 Lux SCSP
Founder
Founder
2024
NR
New Rhein Healthcare 2021 de LP
Founder
Founder
2024
Former (4)
NG
Nayan Gregory Parekh
Chief Executive Officer
Chief Executive Officer
2024 – 2025
EV
Erik Voorspoels
Management
Management
2025 – 2025
ML
Marie Louise Lindegaard
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
Alveus Therapeutics Inc. — 66.67–89.99%
Jeito II S.L.P — 5–9.99%
FPCI BioDiscovery 7 — 5–9.99%
New Rhein Healthcare 2021 Lux SCSP — 50–66.65%
New Rhein Healthcare 2021 de LP — 33.33–49.99%
100%
Shareholder
Type
Ownership
Votes
Since
Alveus Therapeutics Inc.
Company
66.67–89.99%
100%
2026
Jeito II S.L.P
Individual
5–9.99%
0%
2026
FPCI BioDiscovery 7
Individual
5–9.99%
0%
2025
New Rhein Healthcare 2021 Lux SCSP
Individual
50–66.65%
50%
2024
New Rhein Healthcare 2021 de LP
Individual
33.33–49.99%
33.33%
2024
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on Alveus Therapeutics ApS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network
Management
Management
2024 – 2025
LP
Lars Peter Brunse
Management
Management
2024 – 2024